1. Aulton, M. E., Pharmaceutics, second edition, pp. 113–138, Churchill Livingstone, Edinburgh (2002).
2. Botha, S. A. and Lotter, A. P., Compatibility study between ketoprofen and tablet excipients using differential scanning calorimetry.Drug Devel. Ind. Pharm., 15, 415–426 (1989).
3. Haleblian, J. and McCrone, W., Pharmaceutical applications of polymorphism.J. Pharm. Sci., 58, 911–929 (1969).
4. Holgado, M. A., Fernandez-Arevalo, M., Gines, J. M., Caraballo, I., and Labasco, A. M., Compatibility study between carteolol hydrochloride and tablet excipients using differential scanning calorimetry and hot stage microscopy.Pharmazie, 50, 195–198 (1995).
5. Hong, K. W., Kim, K. Y., Lee, J. H., Shin, H. K., Kwak, Y. G., Kim, S. O., Lim, H., and Yoo, S. E., Neuroprotective effect of (2S,3S,4R)-N”-cyano-N-(6-amino-3,4-dihydro-3-hydroxy-2-methyl-2-dimethoxymethyl-2H-benzopyran-4-yl)-N-benzyl-guanidine (KR-31378), a benzopyran analog, against focal ischemic brain damage in rats.J. Phamacol. Exp. Ther., 301, 210–216 (2002).